Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Van Der Leeuw, Christine ^a   Marcelis, Machteld ^a   Peeters, Sanne C T ^a   Verbeek, Marcel M ^b,c   Menheere, Paul P C A ^d   De Haan, Lieuwe ^e   Van Os, Jim ^a,f   Van Beveren, Nico J M ^g,h  

^a European Graduate School of Neuroscience Maastricht   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Delta Center for Mental Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PROTEIN S100B;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NETHERLANDS; PATHOLOGY; PHENOTYPE; POSITIVE SYNDROME; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SIBLING;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84893046640     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082535     Document Type: Article

References (56)

1. van Beveren NJ, Hoogendijk WJ (2011) Clinical utility of serum biomarkers for major psychiatric disorders. Int Rev Neurobiol 101: 351-374.
2. Pillai A, Buckley PF (2012) Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr Clin North Am 35: 645-659.
3. Sen J, Belli A (2007) S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 85: 1373-1380.
4. Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, et al. (2012) The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem 120: 644-659.
5. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. (2009) S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793: 1008-1022.
6. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, et al. (2013) Functions of S100 proteins. Curr Mol Med 13: 24-57.
7. van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D (2006) Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol 16: 469-480.
8. Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, et al. (1999) Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45: 1508-1511.
9. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 167: 66-72.
10. Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, et al. (2003) Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 62: 231-236.
11. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT (2006) Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 77: 1284-1287.
12. Gattaz WF, Lara DR, Elkis H, Portela LV, Goncalves CA, et al. (2000) Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res 43: 91-95.
13. Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, et al. (2004) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9: 897-899.
14. Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: an update. Gen Physiol Biophys 28 Spec No Focus: F76-81.
15. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, et al. (2007) Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 31: 361-364.
16. Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, et al. (2007) Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 41: 36-42.
17. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, et al. (2001) Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6: 445-449.
18. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29: 1004-1011.
19. Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, et al. (2008) S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 42: 868-876.
20. Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, et al. (2010) S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance. Cardiovasc Psychiatry Neurol 2010: 480707.
21. Guest PC, Wang L, Harris LW, Burling K, Levin Y, et al. (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15: 118-119.
22. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, et al. (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93: 572-577.
23. Camchong J, Lim KO, Sponheim SR, Macdonald AW (2009) Frontal white matter integrity as an endophenotype for schizophrenia: diffusion tensor imaging in monozygotic twins and patients' nonpsychotic relatives. Front Hum Neurosci 3: 35.
24. Knochel C, Oertel-Knochel V, Schonmeyer R, Rotarska-Jagiela A, van de Ven V, et al. (2012) Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. Neuroimage 59: 926-934.
25. Clark KA, Nuechterlein KH, Asarnow RF, Hamilton LS, Phillips OR, et al. (2011) Mean diffusivity and fractional anisotropy as indicators of disease and genetic liability to schizophrenia. J Psychiatr Res 45: 980-988.
26. Hao Y, Yan Q, Liu H, Xu L, Xue Z, et al. (2009) Schizophrenia patients and their healthy siblings share disruption of white matter integrity in the left prefrontal cortex and the hippocampus but not the anterior cingulate cortex. Schizophr Res 114: 128-135.
27. Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1: 495.
28. Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, et al. (2008) Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 103: 110-113.
29. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B (2008) Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98: 302-306.
30. Liu J, Shi Y, Tang J, Guo T, Li X, et al. (2005) SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328: 335-341.
31. Zhai J, Cheng L, Dong J, Shen Q, Zhang Q, et al. (2012) S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr Res 134: 89-94.
32. Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L (2012) Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res 21: 205-221.
33. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J (2011) Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol Psychiatry 69: 487-494.
34. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press.
35. Andreasen NC, Flaum M, Arndt S (1992) The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49: 615-623.
36. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
37. Smit LH, Korse CM, Bonfrer JM (2005) Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 20: 34-42.
38. Goldstein H (1987) Multilevel Models in Educational and Social Research. London: Griffin.
39. Clayton D, Hills M (1993) Statistical Models in Epidemiology. Oxford: Oxford University Press.
40. Schroeter ML, Steiner J (2009) Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 14: 235-237.
41. Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, et al. (2010) Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 44: 1236-1240.
42. Gos T, Schroeter ML, Lessel W, Bernstein HG, Dobrowolny H, et al. (2013) S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: A postmortem study. J Psychiatr Res.
43. Ioannidis JP (2011) Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 68: 773-780.
44. Yelmo-Cruz S, Morera-Fumero AL, Abreu-Gonzalez P (2013) S100B and schizophrenia. Psychiatry Clin Neurosci 67: 67-75.
45. Streitburger DP, Arelin K, Kratzsch J, Thiery J, Steiner J, et al. (2012) Validating Serum S100B and Neuron-Specific Enolase as Biomarkers for the Human Brain - A Combined Serum, Gene Expression and MRI Study. PLoS One 7: e43284.
46. Wolkin A, Choi SJ, Szilagyi S, Sanfilipo M, Rotrosen JP, et al. (2003) Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 160: 572-574.
47. Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, et al. (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 33: 976-984.
48. Makris N, Seidman LJ, Ahern T, Kennedy DN, Caviness VS, et al. (2010) White matter volume abnormalities and associations with symptomatology in schizophrenia. Psychiatry Res 183: 21-29.
49. Nakamura K, Kawasaki Y, Takahashi T, Furuichi A, Noguchi K, et al. (2012) Reduced white matter fractional anisotropy and clinical symptoms in schizophrenia: a voxel-based diffusion tensor imaging study. Psychiatry Res 202: 233-238.
50. Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, et al. (2013) Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 70: 472-480.
51. Steiner J, Schroeter ML, Schiltz K, Bernstein HG, Muller UJ, et al. (2010) Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 167: 1025-1031.
52. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, et al. (2001) Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 35: 11-14.
53. Steiner J, Schiltz K, Walter M, Wunderlich MT, Keilhoff G, et al. (2010) S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology 35: 321-324.
54. Donato R, Heizmann CW (2010) S100B Protein in the Nervous System and Cardiovascular Apparatus in Normal and Pathological Conditions. Cardiovasc Psychiatry Neurol 2010: 929712.
55. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, et al. (2010) Extracranial sources of S100B do not affect serum levels. PLoS One 5.
56. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, et al. (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15: 3-4.